# Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

> **NCT01929603** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **PROCEDURE:** Pharmacokinetic sampling
- **DRUG:** Rifampicin
- **DRUG:** Olaparib tablet dosing

## Key facts

- **NCT ID:** NCT01929603
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-05
- **Final completion:** 2016-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929603, "Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01929603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*